COST-SAVING IMPACT OF BIOVOLUME
Greater reproducibility offered by BioVolume could save
$38 million in a drug development cycle. Read our white paper analysis.
In this report we aimed to investigate the impact of adopting BioVolume on the whole drug development cycle, utilising the economic model created by Paul et al in their 2010 analysis.
View and download the paper below:
**Updated 6th October 2022** to version 2 which includes further analysis of the impact by assessing false positives as well as false negatives and the impact that has in later clinical development phases